Mast Therapeutics Inc (NYSEMKT:MSTX) must confront how to move forward in the wake of a sickle cell phase III miss for its pipeline …
Mast Therapeutics Inc (NYSEMKT:MSTX) provided an update related to its business strategy and the clinical development of its product candidates. The Company’s cash, …
Mast Therapeutics Inc (NYSEMKT:MSTX) announced yesterday that its phase III EPIC study results proved to be a “surprising disappointment,” after the firm’s pipeline …
The biotech world is sounding the alarm on Mast Therapeutics Inc (NYSEMKT:MSTX) and Mirna Therapeutics Inc (NASDAQ:MIRN) after MSTX now has a Phase …
Tuesday turned out to be a nightmare for shareholders of Mast Therapeutics Inc (NYSEMKT:MSTX), as the biotech company disclosed that its Phase 3 clinical study …
All sickle cell community and investor eyes are on Mast Therapeutics (NYSEMKT:MSTX) this month, as MSTX prepares to roll out pivotal data from …
In the past week, Mast Therapeutics Inc (NYSEMKT:MSTX) stock has seen a price increase from $0.40 to $0.
Mast Therapeutics Inc (NYSEMKT:MSTX), a biopharmaceutical company developing novel, clinical-stage therapies for sickle cell disease and heart failure, today announced that it is …
In a research note released Tuesday, Maxim analyst Jason McCarthy reiterated a Buy rating on shares of Mast Therapeutics Inc (NYSEMKT:MSTX), with a $5.00 price target, …
Mast Therapeutics Inc (NYSEMKT:MSTX), a biopharmaceutical company developing novel, clinical-stage therapies for sickle cell disease and heart failure, today reported financial results for the …
